Naito, R., Mizokami, A., Izumi, K., Iwamoto, H. (2026). Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps272